Abstract:Background: Long non-coding RNA (lncRNA) plays a significant role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). This article aims to develop an immune-related lncRNA (irlncRNA) model, regardless of expression levels, for risk assessment and prognosis prediction in HNSCC patients. Methods: We obtained clinical data and corresponding full transcriptome expression of HNSCC patients from TCGA, downloaded GTF files to distinguish lncRNAs from Ensembl, discerned irlncRNAs based on co-expression analysis, distinguished differentially expressed irlncRNAs (DEirlncRNAs), and paired these DEirlncRNAs. Univariate Cox regression analysis, LASSO regression analysis, and stepwise multivariate Cox regression analysis were then performed to screen lncRNA pairs, calculate the risk coefficient, and establish a prognosis model. Finally, the predictive power of this model was validated through the AUC and the ROC curves, and the AIC values of each point on the five-year ROC curve were calculated to select the maximum inflection point, which was applied as a cut-off point to divide patients into low- or high-risk groups. Based on this methodology, we were able to more effectively differentiate between these groups in terms of survival, clinico-pathological characteristics, tumor immune infiltrating status, chemotherapeutics sensitivity, and immunosuppressive molecules. Results: A 13-irlncRNA-pair signature was built, and the ROC analysis demonstrated high sensitivity and specificity of this signature for survival prediction. The Kaplan–Meier analysis indicated that the high-risk group had a significantly shorter survival rate than the low-risk group, and the chi-squared test certified that the signature was highly related to survival status, clinical stage, T stage, and N stage. Additionally, the signature was further proven to be an independent prognostic risk factor via the Cox regression analyses, and immune infiltrating analyses showed that the high-risk group had significant negative relationships with various immune infiltrations. Finally, the chemotherapeutics sensitivity and the expression level of molecular markers were also significantly different between high- and low-risk groups. Conclusion: The signature established by paring irlncRNAs, with regard to specific expression levels, can be utilized for survival prediction and to guide clinical therapy in HNSCC.

Immune‐relatedlncRNAs Can Predict the Prognosis of Acute Myeloid Leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

Immune-related lncRNAs pairs prognostic score model for prediction of survival in acute myeloid leukemia patients

A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.

Identification of the Integrated Prognostic Signature Associated with Immuno-relevant Genes and Long Non-coding RNAs in Acute Myeloid Leukemia

An Immunogenic Cell Death-Based Risk model Predicts Prognosis and Indicates Immune Infiltration Landscape in Acute Myeloid Leukemia

Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia

Identification and Experimental Validation of Immune-Associate Lncrnas for Predicting Prognosis in Cervical Cancer

Development and Validation of a Novel Prognostic Model for Acute Myeloid Leukemia Based on Immune-Related Genes

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

A Novel Immune-Related Competing Endogenous RNA Network Predicts Prognosis of Acute Myeloid Leukemia

N6-Methyladenosine-Related Lncrnas Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia

m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia

DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data

An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer

Immune-Related lncRNA Signature for Predicting the Immune Landscape of Head and Neck Squamous Cell Carcinoma

A Novel Immune-Related Long Non-Coding RNAs Risk Model for Prognosis Assessment of Lung Adenocarcinoma.

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia

A 10-Long Non-Coding RNA-Based Expression Signature As a Potential Biomarker for Prognosis of Acute Myeloid Leukemia

m6A-Related lncRNAs Affect Tumor Immune Microenvironment And Prognosis In Acute Myeloid Leukemia

Using Immune-Related Long Non-coding Ribonucleic Acids to Develop a Novel Prognosis Signature and Predict the Immune Landscape of Colon Cancer